B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by PharmaCyte Biotech, Inc.

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers FEMY PMCB
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Announces Final Results of Tender Offer
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
From PharmaCyte Biotech, Inc.
Via Business Wire
Tickers PMCB
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.